1.Recent advances on physical ablation for tumor.
Chengxiang LI ; Chenguo YAO ; Yaen MI ; Zheng'ai XIONG
Journal of Biomedical Engineering 2009;26(5):1137-1140
Physical ablation is a new kind of tumor treatment which directly acts on local solid tumors to eradicate or destroy tumor tissues by use of various advanced physical techniques. Physical ablation can be classified by physical characteristics as thermal ablate therapy (TAT), cryoablation and electrical ablation. Recent studies and technical trend of these three physical ablation treatments are reviewed in this paper.
Animals
;
Catheter Ablation
;
methods
;
Cryosurgery
;
Humans
;
Hyperthermia, Induced
;
Neoplasms
;
surgery
;
therapy
;
Salvage Therapy
2.Application of Ilizarov technique in salvage ankle arthrodesis.
Hong-quan JI ; Paul PINCUS ; Geng-ting DANG
Chinese Journal of Surgery 2003;41(6):441-444
OBJECTIVETo introduce the application of Ilizarov technique in ankle fusion with serious pathology and failed ankle arthrodesis.
METHODThe medical records and images of 9 cases of complex ankle fusion using Ilizarov external fixator were analyzed. Among the 9 cases, 6 received revisional ankle fusion, and 3 primary fusion for septic arthritis. All the cases were followed up for an average of 18.1 months.
RESULTSSix cases showed good results, i.e, no or mild pain, occasional limp and stable fusion and 3 cases fair results, i.e, moderate pain, persistent limp or occupational restriction, and stable fusion.
CONCLUSIONIlizarov technique is one of the effective method for the treatment of complex ankle arthrodesis.
Adult ; Aged ; Ankle Joint ; surgery ; Arthrodesis ; methods ; Female ; Humans ; Ilizarov Technique ; Male ; Middle Aged ; Salvage Therapy
4.Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?.
Gut and Liver 2015;9(5):567-568
No abstract available.
Colitis, Ulcerative/*drug therapy
;
Cyclosporine/*therapeutic use
;
Female
;
Humans
;
Immunosuppressive Agents/*therapeutic use
;
Infliximab/*therapeutic use
;
Male
;
Salvage Therapy/*methods
6.Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: Systemic review and meta-analysis of 5-year and 10-year follow-up data.
Ja Yoon KU ; Chan Ho LEE ; Hong Koo HA
Korean Journal of Urology 2015;56(11):735-741
PURPOSE: To evaluate the oncologic outcomes between adjuvant radiotherapy (ART) and salvage radiotherapy (SRT) in patients with locally advanced prostate cancer or with adverse pathologic factors including positive surgical margin and high Gleason score. MATERIALS AND METHODS: We searched the literature published from January 2000 until December 2014 at MEDLINE, PubMed, Web of Science, Embase, ProQuest, and Cochrane Library. To be specific, included were studies comparing ART and SRT settings if they followed up oncologic outcomes more than 5 years. RESULTS: Overall, 3 retrospective, nonrandomized, observational studies, 1 matched control analysis, and 3 prospective randomized controlled studies met our inclusion criteria including a total of 2,380 patients (1,192 ART vs. 1,188 SRT). Higher favorable results were found in ART than in SRT was seen in the 5-year and 10-year biochemical recurrence (BCR)-free survival (risk ratio [RR], 0.61 and 0.70; 95% confidence interval [CI], 0.54-0.69 and 0.63-0.76). ART had a significantly higher 5-year progression-free survival rate than that in SRT (RR, 0.64; 95% CI, 0.51-0.80), but this was not the same for the 10-year progression-free survival rate (RR, 0.88; 95% CI, 0.72-1.08). There was no significant difference for the 5-year and 10-year overall survival rates between ART and SRT (RR, 0.80 and 0.94; 95% CI, 0.59-1.07 and 0.80-1.11). CONCLUSIONS: ART showed favorable results in BCR-free survival during the 5-year follow-up period. However, the 10-year progression-free survival and overall survival did not show any difference between ART and SRT.
Follow-Up Studies
;
Humans
;
Male
;
Prostatic Neoplasms/*radiotherapy/surgery
;
Publication Bias
;
Radiotherapy, Adjuvant
;
Salvage Therapy/*methods
;
Sensitivity and Specificity
;
Treatment Outcome
7.Current Status of Cryotherapy for Prostate and Kidney Cancer.
Korean Journal of Urology 2014;55(12):780-788
In terms of treating diseases, minimally invasive treatment has become a key element in reducing perioperative complications. Among the various minimally invasive treatments, cryotherapy is often used in urology to treat various types of cancers, especially prostate cancer and renal cancer. In prostate cancer, the increased incidence of low-risk, localized prostate cancer has made minimally invasive treatment modalities an attractive option. Focal cryotherapy for localized unilateral disease offers the added benefit of minimal morbidities. In renal cancer, owing to the increasing utilization of cross-sectional imaging, nearly 70% of newly detected renal masses are stage T1a, making them more susceptible to minimally invasive nephron-sparing therapies including laparoscopic and robotic partial nephrectomy and ablative therapies. This article reviews the various outcomes of cryotherapy compared with other treatments and the possible uses of cryotherapy in surgery.
Cryosurgery/adverse effects/*methods
;
Humans
;
Kidney Neoplasms/*surgery
;
Male
;
Minimally Invasive Surgical Procedures/adverse effects/methods
;
Prostatic Neoplasms/*surgery
;
Salvage Therapy/methods
;
Treatment Outcome
9.Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine.
Chinese journal of integrative medicine 2011;17(3):228-231
"Living with cancer" and symptom control are the features and advantages of integrative medicine in advanced non-small cell lung cancer (NSCLC) treatment. However, with the current concept of response evaluation criteria by the WHO and RECIST, it is difficult to exhibit the above characteristics. Clinical benefit (CB) is designed as an endpoint recently widely understood and accepted in oncology clinical trials. With the review of its definition and development, we suggest CB to be used as an endpoint in advanced NSCLC treatment with integrative medicine. CB should encompass two connotations: one is improved quality of life and symptom control and the other is disease control rate (DCR), including complete response (CR), partial response (PR), and stable disease (SD). We need to design randomized controlled trials (RCT) to investigate the interrelationship of CB rate and survival to provide high-grade evidence proving that advanced lung cancer patients could really benefit from integrative medicine treatment.
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
pathology
;
therapy
;
Combined Modality Therapy
;
Disease Progression
;
Endpoint Determination
;
methods
;
Humans
;
Integrative Medicine
;
methods
;
Lung Neoplasms
;
diagnosis
;
pathology
;
therapy
;
Risk Assessment
;
Salvage Therapy
10.Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
Jeongshim LEE ; Sung Soo AHN ; Jong Hee CHANG ; Chang Ok SUH
Yonsei Medical Journal 2018;59(2):194-201
PURPOSE: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recurrent glioblastoma (GBM) and related prognosticators of outcomes. MATERIALS AND METHODS: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume. RESULTS: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization. CONCLUSION: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with small-sized recurrences in non-eloquent areas and good performance.
Adult
;
Brain Neoplasms/mortality/pathology/*therapy
;
Dose Hypofractionation
;
Female
;
Glioblastoma/mortality/pathology/*therapy
;
Humans
;
Karnofsky Performance Status
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality/pathology/*therapy
;
Prognosis
;
*Radiosurgery
;
Re-Irradiation/*methods
;
Salvage Therapy/methods
;
Survival Rate
;
Treatment Outcome